Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,839.00
Bid: 6,838.00
Ask: 6,840.00
Change: 45.00 (0.66%)
Spread: 2.00 (0.03%)
Open: 6,779.00
High: 6,873.00
Low: 6,761.00
Yest. Close: 6,794.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Astrazeneca wins approval for new antibiotic in fight against drug resistance

(ShareCast News) - AstraZeneca has won European regulatory approval for Zavicefta, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics. Zavicefta, a combination of ceftazidime

28 Jun 16 07:08

AstraZeneca Gets EU Approval For Zavicefta Antibiotic Treatment

28 Jun 16 06:44

Sunday share tips: EasyJet, Randgold, Imperial Brands, AstraZeneca

(ShareCast News) - Sell EasyJet shares due to the likely turbulence sparked by the Brexit vote, said the Sunday Times' Inside the City column. The budget airline was created by Stelios Haji-Ioannou in the wake of the 1992 European Union Treaty on Open Skies, one of the supposedly rare bits of Brusse

26 Jun 16 14:03

Britain's FTSE closes down 3.2 pct, banks and housebuilders slump

By Sudip Kar-Gupta LONDON, June 24 (Reuters) - Britain's top shares index fell on Friday, led lower by banks and homebuilders, but staged a sharp recovery from its initial slump caused by the country's decision to leave the European Union. The FTSE 100 index initially dived more than

24 Jun 16 15:54

UPDATE 2-From drinks to drugs to cars: Global business hit by EU vote

(Adds further details from companies) By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Chief executives from Tokyo to Denver prepared for long-term disruption, job cuts and lower profits on Friday after Britain's vote to leave the European Union raised widespread fears

24 Jun 16 15:43

UPDATE 1-From beer to drugs to cars: Global business laments EU vote

By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Chief executives from Tokyo to Denver woke up on Friday to currency turmoil, plunging share prices and tough decisions after Britain's vote to leave the European Union raised widespread fears over economic growth. In Bri

24 Jun 16 11:32

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

24 Jun 16 09:49

UPDATE: UK Chemicals And Pharmaceuticals Must "Look To Future"

24 Jun 16 07:44

From beer to drugs to cars: Global business laments EU vote

By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Shocked chief executives from Mumbai to Denver woke up on Friday to face tough decisions over how to respond to Britain's vote to leave the European Union. In Britain itself, businesses as diverse as engineering group Ro

24 Jun 16 06:50

UPDATE 3-U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds expert's comments) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effe

23 Jun 16 19:36

UPDATE 2- U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds details from CDC, background, byline, dateline) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the na

23 Jun 16 18:00

UPDATE 1-AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

(Adds shares, analyst comment, further details) By Ben Hirschler LONDON, June 23 (Reuters) - AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not

23 Jun 16 09:57

UPDATE: AstraZeneca To Take Writedown As FluMist Is Not Recommended

23 Jun 16 09:17

US authorities recommend against AstraZeneca flu vaccine

(ShareCast News) - Pharmaceutical giant AstraZeneca confirmed disappointing news to investors on Thursday, with updated guidance from US regulators recommending against its FluMist Quadrivalent influenza vaccine. The FTSE 100 firm said the updated guidance from the Advisory Committee on Immunization

23 Jun 16 07:32

AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

LONDON, June 23 (Reuters) - AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not use the product. The U.S. Centers for Disease Control and Prevention (C

23 Jun 16 06:45

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.